


DAKLINZA[®]

daclatasvir

PRODUCT INFORMATION

NAME OF THE MEDICINE

DAKLINZA (daclatasvir), is a highly selective inhibitor of HCV nonstructural protein 5A (NS5A) replication complex. The chemical name for daclatasvir dihydrochloride is carbamic acid, *N,N'*-[[1,1'-biphenyl]-4,4'-diylbis[1*H*-imidazole-5,2-diyl-(2*S*)-2,1-pyrrolidinediyl[(1*S*)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]bis-, *C,C'*-dimethyl ester, hydrochloride (1:2). Daclatasvir dihydrochloride has the following structural formula:



CAS number: 1009119-65-6

Molecular formula: C₄₀H₅₀N₈O₆.2HCl

Molecular weight: 738.88 (free base); 811.80 (dihydrochloride salt)

DESCRIPTION

Daclatasvir drug substance is white to yellow. Daclatasvir dihydrochloride is freely soluble in water.

DAKLINZA 60 mg tablets contain the inactive ingredients anhydrous lactose (116 mg), microcrystalline cellulose, croscarmellose sodium, silicon dioxide, magnesium stearate, and OPADRY complete film coating system 03B110007 Green (proprietary ingredient number109448).

DAKLINZA 30 mg tablets contain the inactive ingredients anhydrous lactose (58 mg), microcrystalline cellulose, croscarmellose sodium, silicon dioxide, magnesium stearate, and OPADRY complete film coating system 03B110005 Green (proprietary ingredient number109451).

DAKLINZA 90 mg tablets contain the inactive ingredients anhydrous lactose (173 mg), microcrystalline cellulose, croscarmellose sodium, silicon dioxide, magnesium stearate, and OPADRY complete film coating system 03B110005 Green (proprietary ingredient number 109451).

Opadry green contains hypromellose, titanium dioxide, Macrogol 400, indigo carmine aluminum lake, and iron oxide yellow.

PHARMACOLOGY

Mechanism of Action

Daclatasvir is a direct acting antiviral agent (DAA) against the hepatitis C virus. Daclatasvir is an inhibitor of NS5A, a multifunctional protein that is an essential component of the HCV replication complex. Daclatasvir inhibits both viral RNA replication and virion assembly. *In vitro* and computer modelling data indicate that daclatasvir interacts with the N-terminus within Domain 1 of the protein, which may cause structural distortions that interfere with NS5A functions.

Antiviral Activity

Daclatasvir is a potent pan-genotypic NS5A replication complex inhibitor with effective concentration (50% reduction, EC₅₀) values from pM to low nM. EC₅₀ values of daclatasvir range from 0.001 to 1.25 nM in genotype 1a, 1b, 3a, 4a, 5a, and 6a, and from 0.034 to 19 nM in genotype-2a cell-based replicon assays. In addition, daclatasvir inhibits infectious genotype 2a (JFH-1) virus with EC₅₀ value of 0.020 nM. In HCV genotype 1a infected subjects, a single 60 mg dose of daclatasvir resulted in a 3.2 log₁₀ IU/mL mean reduction in viral load measured after 24 hours.

Daclatasvir showed additive to synergistic interactions with interferon alfa, HCV NS3 protease inhibitors, HCV NS5B non-nucleoside inhibitors, and HCV NS5B nucleoside analogs in combination studies using the cell-based HCV replicon system. No antagonism of antiviral activity was observed.

Resistance

In cell culture

Substitutions conferring daclatasvir resistance in HCV genotypes 1-6 were selected in the cell-based replicon system and observed in the N-terminal 100 amino acid region of NS5A. L31V and Y93H were frequently observed resistance substitutions in genotype 1b, while M28T, L31V/M, Q30E/H/R, and Y93C/H/N were frequently observed resistance substitutions in genotype 1a. Single amino acid substitutions generally conferred low level resistance (EC₅₀ <1 nM for L31V, Y93H) for genotype 1b, and higher levels of resistance for genotype 1a (up to 350 nM for Y93N). Resistance patterns observed in the clinic are very similar to patterns generated *in vitro* except that linked substitutions are more complex in clinical specimens.

The majority of wild-type HCV genotype 2a contain a pre-existing resistance substitution (L31M) with EC₅₀ values of 9 to 19 nM. The most resistant variants with a single amino acid substitution were F28S (EC₅₀ >500 nM) for genotype 2a, Y93H (EC₅₀ >680 nM) for genotype 3a, L31F (EC₅₀ 6.9 nM) for genotype 5a, and P32L (EC₅₀ 250nM) for genotype 6a. In genotype 4, amino acid substitutions at 30 and 93 (EC₅₀ < 16 nM) were frequently selected.

In clinical studies

Effect of Baseline HCV Polymorphisms on Treatment Response

Analyses were conducted to explore the association between naturally occurring baseline NS5A amino acid substitutions (polymorphisms) and treatment outcome. The impact of NS5A polymorphisms is regimen specific.

DAKLINZA in combination with sofosbuvir: In a pooled analysis of Phase 2 and 3 studies where patients received daclatasvir and sofosbuvir with or without ribavirin for 12 or 24 weeks, baseline NS5A polymorphisms at amino acid positions associated with daclatasvir

resistance (28, 30, 31 or 93) were detected in 19% (116/605) of patients (32/295 genotype 1a, 15/75 genotype 1b, 33/36 genotype 2, 31/192 genotype 3, 4/6 genotype 4 and 1/1 genotype 6) with available baseline NS5A sequence. These NS5A polymorphisms included M28T/V, Q30E/H/L/R, L31M or Y93C/H/L/N/S in genotype 1a patients; R30K/M/Q, L31M or Y93H in genotype 1b patients; F28L or L31M in genotype 2 patients; M28V, A30E/K/S/T/V, L31M or Y93H in genotype 3 patients; L28M or L30R in genotype 4 patients; and F28M/V and R30S in genotype 6 patients.

Overall SVR12 rates for patients with or without baseline NS5A polymorphisms at 28, 30, 31 or 93 were 88% (102/116) and 96% (469/489), respectively (see Table 1). In patients without cirrhosis, the SVR12 rates in patients with and without baseline NS5A polymorphisms were high: 95% (83/87) and 99% (350/353), respectively. In patients with cirrhosis, SVR12 rates with and without baseline NS5A polymorphisms were 53% (11/21) and 85% (77/91), respectively. Specific baseline NS5A polymorphisms in the 10 patients with cirrhosis who failed were: M28T (n = 1), L31M (n = 2, both Child-Pugh B) and Y93N (n = 1) in patients with genotype 1a; A30K (n = 1), Y93H (n = 3) and A30T (n = 1) in patients with genotype 3; and L31M (n = 1, Child-Pugh C) in a patient with genotype 2. All of the described genotype 1a, genotype 2, and genotype 3 NS5A substitutions confer a greater than 100-fold reduction in daclatasvir activity in vitro, except for A30T which was only detected at baseline and not at failure. For the 14 patients with cirrhosis who failed without noted baseline NS5A polymorphisms, 6 patients had Child-Pugh C liver disease.

The sofosbuvir resistance-associated substitution S282T was not detected in the baseline NS5B sequence of any patient in Phase 2 or 3 studies by population-based sequencing.

Table 1: Impact of baseline NS5A polymorphisms (at amino acid positions 28, 30 31 or 93) on SVR12 response in patients with/without baseline cirrhosis treated with daclatasvir and sofosbuvir with/without ribavirin for at least 12 weeks

	SVR12 Rates in Patients with NS5A Sequences	
	With Noted Baseline NS5A Polymorphisms*	Without Noted Baseline NS5A Polymorphisms
Overall**	88% (102/116)	96% (469/489)
Patients without Cirrhosis	95% (83/87)	99% (350/353)
Genotype 1a	100% (24/24)	100% (186/186)
Genotype 1b	100% (11/11)	100% (42/42)
Genotype 2	100% (27/27)	100% (3/3)
Genotype 3	83% (19/23)	98% (118/121)
Genotype 4	100% (2/2)	100% (1/1)
Patients with Cirrhosis	52% (11/21)	85% (77/91)
Genotype 1a	33% (2/6)	88% (42/48)
Genotype 1b	0	100% (12/12)
Genotype 2	83% (5/6)	0
Genotype 3	29% (2/7)*	73% (22/30)

Table 1: Impact of baseline NS5A polymorphisms (at amino acid positions 28, 30 31 or 93) on SVR12 response in patients with/without baseline cirrhosis treated with daclatasvir and sofosbuvir with/without ribavirin for at least 12 weeks

SVR12 Rates in Patients with NS5A Sequences		
	With Noted Baseline NS5A Polymorphisms*	Without Noted Baseline NS5A Polymorphisms
Genotype 4	100% (2/2)*	100% (1/1)

* Two patients with cirrhosis (1 genotype 3, 1 genotype 4) each with Child-Pugh C cirrhosis who received daclatasvir and sofosbuvir with ribavirin were classified as nonvirologic failures due to data not being available for the integrated analysis although they achieved SVR12; both patients had noted baseline NS5A polymorphisms (genotype 3: A30K; genotype 4: L28M) and are not included in this analysis.

** For 53 post-liver transplant patients treated with daclatasvir and sofosbuvir ± ribavirin for 12 weeks, the presence of baseline NS5A polymorphisms (at 28, 30, 31 or 93) did not appear to impact response rates since all patients (n = 8) with these polymorphisms achieved SVR12. The overall total row in the table includes this patient population, but they are not included in the rows for patients with and without cirrhosis.

In a pooled analysis of 629 patients who received daclatasvir/sofosbuvir with or without ribavirin in Phase 2 and 3 studies, 44 patients (19 with genotype 1a, 2 with genotype 1b, 2 with genotype 2, and 21 with genotype 3) qualified for resistance analysis due to virologic failure or early study discontinuation and having HCV RNA greater than 1,000 IU/ml. Post-baseline NS5A and NS5B sequencing (assay cut-off of 20%) were available for 44/44 and 39/44 patients, respectively.

NS5A resistance-associated variants (RAVs) were observed in post-baseline isolates from 37/44 patients (13/19 with genotype 1a, 1/2 with genotype 1b, 2/2 with genotype 2, and 21/21 with genotype 3) not achieving SVR. Thirteen (68%) of the 19 patients with HCV genotype 1a who qualified for resistance testing harboured one or more NS5A RAVs at positions M28, Q30, L31, H58 or Y93. Five of the patients with genotype 1a also had Child-Pugh C liver disease. Two patients had the same NS5A RAVs at baseline and post-baseline (M28T or Y93N). Substitutions at Q30 were most frequently observed (Q30E/H/K/R; 10/19 [52.6%]). Of the 2 patients with genotype 1b who qualified for resistance testing, a deletion at NS5A-P32 was observed in 1 patient. The 2 patients with genotype 2 who qualified for resistance testing had the same NS5A RAVs at baseline and post-baseline (L31M). Of the 21 patients with genotype 3 who qualified for resistance testing, 21 (100%) patients harboured one or more NS5A RAVs at positions 30, 31, 62 or 93. Substitutions at Y93 were most frequently observed (17/21 [81%]) and were observed at baseline in 6 patients and only post-baseline in 11 patients. Among the 7 patients who had no NS5A RAVs at failure, all received daclatasvir/sofosbuvir for 8 weeks. All of the described genotype 1a Q30 substitutions, genotype 1b P32 deletion, genotype 2 L31M, and genotype 3 Y93H conferred reduced susceptibility to daclatasvir *in vitro* (fold-change in EC₅₀ values ≥900).

Limited data on the persistence of daclatasvir resistance-associated substitutions are available

DAKLINZA in combination with asunaprevir (SUNVEPRA®): In a pooled analysis of treatment-naïve and treatment-experienced HCV genotype 1b infected subjects from phase 2/3 clinical trials, the efficacy of DAKLINZA in combination with SUNVEPRA was reduced in subjects whose virus had NS5A sequence polymorphisms detected at L31 (F, I, M or V) or Y93 (H). The pooled SVR rate in phase 2/3 trials for patients whose virus had

L31F/I/M/V or Y93H was 48/119 (40%) compared with 686/742 (93%) for patients whose virus lacked L31F/I/M/V or Y93H polymorphisms. Among 863 HCV genotype 1b infected patients in phase 2/3 clinical trials with available NS5A sequence data, the prevalence of NS5A polymorphisms L31F/I/M/V or Y93H at baseline was 14%; 4% had virus with L31F/I/M/V without Y93H, 10% had virus with Y93H without L31F/I/M/V, and 0.5% had virus with L31F/I/M/V +Y93H. Of 127 virologic failures with baseline NS5A sequence data, 16% had L31F/I/M/V alone, 38% had Y93H alone, and 2% had L31F/I/M/V+Y93H.

DAKLINZA in combination with SUNVEPRA, Peginterferon alfa, and Ribavirin: Of 373 subjects with baseline NS5A sequence data in HALLMARK QUAD [see CLINICAL TRIALS], 42 had pre-existing daclatasvir-resistant substitutions. Of these 42 subjects, 38 achieved SVR12, 1 was a non-virologic failure, and 3 experienced virologic failure (1 genotype 1a had NS5A-L31M and 1 had NS5A-Y93F at baseline; 1 genotype 1b had NS5A-L31M at baseline).

Treatment-emergent resistance substitutions in subjects not achieving SVR

DAKLINZA in combination with sofosbuvir: Of 211 subjects from study AI444040 treated with DAKLINZA and sofosbuvir, there was a single genotype 3 subject with virologic relapse. NS5A resistance-associated substitutions observed at failure (A30K, S62I) were also detected at baseline [see CLINICAL TRIALS]. NS5B resistance-associated substitutions were not detected by standard sequencing methods.

Of 418 subjects treated in the ALLY-1, -2, and -3 trials with DAKLINZA and sofosbuvir with or without ribavirin for 12 weeks, 33 subjects (12/169 with genotype 1a, 1/44 with genotype 1b, 1/18 with genotype 2, and 19/178 with genotype 3) qualified for resistance analysis due to virologic failure or early study discontinuation and HCV RNA greater than 1000 IU/mL. Postbaseline NS5A and NS5B sequencing (assay cut-off of 20%) were available for 33/33 and 30/33 subjects, respectively. Virus from all 33 subjects at the time of virologic failure harbored one or more of the following NS5A resistance-associated substitutions: M28T, Q30H/K/R, L31M/V, H58D/P, or Y93C/N (genotype 1a), L31M (genotype 2), A30K/S, L31I, S62A/L/P/T, or Y93H (genotype 3). The most common NS5A amino acids with resistance substitutions were Q30 (Q30 H/K/R; 75% [9/12]) in GT-1a failures, deletion of P32 (P32X) in a GT-1b failure, and Y93 (Y93H; 89% [17/19]) in GT-3 failures. For NS5B, 5 of 30 subjects at the time of virologic failure had virus with previously reported NS5B resistance-associated substitutions: A112T, L159F, or E237G (genotype 1a), S282T (genotype 3).

DAKLINZA in combination with SUNVEPRA: In a pooled analysis of HCV genotype 1b infected patients treated with DAKLINZA and SUNVEPRA, treatment-emergent NS5A amino acid substitutions were detected in the viruses from 116/117 (99%) patients who experienced virologic failure and had available resistance data (see Table 1). Most of these patients (105/117, 90%) had virus with treatment-emergent substitutions at NS5A amino acid positions L31 and/or Y93. Of 121 patients with available resistance data for both NS5A and NS3, 95 (79%) patients had virus with both D168 substitutions NS3 and L31 plus Y93H substitutions in NS5A.

DAKLINZA in combination with SUNVEPRA, Peginterferon alfa, and Ribavirin: Treatment-emergent NS5A amino acid substitutions were detected in the viruses of 17/17 (100%) HCV genotype 1a infected patients who experienced virologic failure with DAKLINZA, SUNVEPRA, peginterferon alfa, and ribavirin (see Table 2); 15/16 (94%) patients with available data had virus with treatment-emergent asunaprevir resistance-associated substitutions in NS3. Treatment-emergent substitutions at NS5A position Q30 were most commonly observed (88%, 15/17). A single HCV genotype 1b infected patient

who experienced virologic failure had virus with treatment-emergent substitutions in NS5A and NS3.

Table 2: Treatment-Emergent NS5A Amino Acid Substitutions in Pooled Data from Phase 2 and Phase 3 Clinical Trials: Subjects who did not Achieve SVR with DAKLINZA and SUNVEPRA, with DAKLINZA and Sofosbuvir or with DAKLINZA, SUNVEPRA, Peginterferon Alfa, and Ribavirin

Treated Subjects	DAKLINZA and SUNVEPRA	DAKLINZA, SUNVEPRA, Peginterferon Alfa, and Ribavirin			DAKLINZA and Sofosbuvir
	Genotype 1b n = 141	Genotype 1a n= 23 ^a	Genotype 1b n = 1 ^a	Genotype 4 n= 0 ^a	Genotype 1, 2, 3 n= 18
Treated subjects with NS5A sequence	117	20	1	0	17
Emergent substitution at NS5A position 28, 29, 30, 31, 32, 54, 58, 62, 93	99 (116)	100 (17)	0	0	71 (12)
R30: G, H, P, Q	9 (11)	NA	0	NA	0
Q30: E, H, K, R	NA	88 (15)	NA	NA	0
L31: F, I, L, M, V	67 (78)	35 (6)	100 (1)	0	6 (1)
P58: A, G, S	10 (12)	NA	0	0	0
Y93: C, H, N	51 (60)	35 (6)	100 (1)	0	0
Y93H	50 (58)	12 (2)	100 (1)	0	53 (9)
Only Q30X ^b	NA	29 (5)	NA	NA	0
Q30 + other noted NS5A substitutions ^c	NA	59 (10)	NA	NA	0
L31X and Y93X ^d	28 (33)	0	100 (1)	0	0
GT-1b: L28M/T, P29S/Δ ^e , P32F/L/Δ, Q54H, or Q62D	Less than 10%	0	0	0	0

^a Of the 26 patients who were considered non SVR12 by a modified intent-to-treat analysis (subjects with missing values for a given time point were considered as a failure for the specific time point only), 2 subjects (1 with HCV genotype 1a and 1 with HCV genotype 4) achieved SVR12 by an imputed analysis (for subjects missing post-treatment week 12 HCV RNA, the next subsequent HCV RNA value was used). One subject with HCV genotype 1b had undetectable HCV RNA at Week 24 (last visit).

^b X represents E, H, K, or R

^c Other noted NS5A substitutions include M28T, L31M/V, E62V or Y93H/N

^d X represents L31F, I, M or V and Y93H or N.

^e Δ represents a deletion of the designated amino acid.

NA = not applicable

Persistence of Resistance-Associated Substitutions

Persistence of emergent NS5A resistance-associated substitutions was monitored post-treatment in subjects who failed daclatasvir containing regimens in phase 2/3 clinical trials. Among subjects treated with DAKLINZA and SUNVEPRA, emergent genotype 1b NS5A resistance-associated substitutions remained at detectable levels in all subjects monitored; 31 subjects only monitored at 24 weeks post-treatment and 9 subjects monitored for 36 weeks or more post treatment. No data on the persistence of daclatasvir resistance-associated substitutions are available from study ALLY-3. The long-term clinical impact of virus containing emergent daclatasvir resistant substitutions is unknown.

Cross-resistance

HCV replicons expressing daclatasvir-associated resistance substitutions remained fully sensitive to interferon alfa and other anti-HCV agents with different mechanisms of action, such as NS3 protease and NS5B polymerase inhibitors (nucleoside and non-nucleoside).

Pharmacokinetics

The pharmacokinetic properties of daclatasvir were evaluated in healthy adult subjects and in subjects with chronic HCV. Following multiple oral doses of daclatasvir 60 mg once daily in combination with peginterferon alfa and ribavirin in HCV-infected subjects, the geometric mean (CV%) daclatasvir C_{max} was 1534 (58) ng/mL, AUC_{0-24h} was 14122 (70) ng•h/mL, and C_{min} was 232 (83) ng/mL.

Absorption

Daclatasvir administered as a tablet was readily absorbed following multiple oral doses with peak plasma concentrations occurring between 1 and 2 hours. Daclatasvir C_{max} , AUC, and C_{min} increased in an approximately dose-proportional manner. Steady state was achieved after 4 days of once-daily administration. At the 60 mg dose, exposure to daclatasvir was similar between healthy and HCV-infected subjects.

In vitro studies with human Caco-2 cells indicated that daclatasvir is a substrate of P-gp. The absolute bioavailability of the tablet formulation is 67%.

In healthy subjects, administration of daclatasvir 60 mg tablet after a high-fat meal (approximately 1000 kcal, approximately 50% from fat) decreased daclatasvir C_{max} and AUC by 28% and 23%, respectively, compared with administration under fasting conditions. Administration of daclatasvir 60 mg tablet after a light meal (approximately 275 kcal, approximately 15% from fat) resulted in no reduction in daclatasvir exposure [see DOSAGE AND ADMINISTRATION].

Distribution

At steady state, protein binding of daclatasvir in HCV-infected subjects was approximately 99% and independent of dose at the dose range studied (1 mg to 100 mg). In subjects who received daclatasvir 60 mg tablet orally followed by 100 μ g [^{13}C , ^{15}N]-daclatasvir intravenous dose, estimated volume of distribution at steady state was 47.1 L. *In vitro* studies indicate that daclatasvir is actively and passively transported into hepatocytes. The active transport is mediated by OCT1 and other unidentified uptake transporters, but not by organic anion transporter (OAT) 2, sodium-taurocholate cotransporting polypeptide (NTCP), or OATPs.

Metabolism

In vitro studies demonstrate that daclatasvir is a substrate of CYP3A, with CYP3A4 the major CYP isoform responsible for the metabolism. No metabolites circulated at levels more than 5% of the parent concentration.

Excretion

Following single-dose oral administration of ¹⁴C–daclatasvir in healthy subjects, 88% of total radioactivity was recovered in faeces (53% as unchanged drug) and 6.6% was excreted in the urine (primarily as unchanged drug). These data indicate that the liver is the major clearance organ for daclatasvir in humans. *In vitro* studies indicate that daclatasvir is actively and passively transported into hepatocytes. The active transport is mediated by OCT1 and other unidentified uptake transporters. Following multiple-dose administration of daclatasvir in HCV-infected subjects, the terminal elimination half-life of daclatasvir ranged from 12 to 15 hours. In subjects who received daclatasvir 60 mg tablet orally followed by 100 µg [¹³C, ¹⁵N]- daclatasvir intravenous dose, the total clearance was 4.24 L/h.

Special Populations

Hepatic Impairment

No dose adjustment of DAKLINZA is necessary for patients with mild (Child-Pugh A), moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment [see PRECAUTIONS, Hepatic Impairment and Cirrhosis].

The pharmacokinetics of daclatasvir following a 30 mg single dose were studied in non-HCV infected subjects with mild, moderate, and severe hepatic impairment compared with unimpaired subjects. The C_{max} and AUC of total daclatasvir (free and protein-bound drug) were lower in subjects with hepatic impairment; however, hepatic impairment did not have a clinically significant effect on the free drug concentrations of daclatasvir.

Renal Impairment

No dose adjustment of DAKLINZA is necessary for patients with any degree of renal impairment [see PRECAUTIONS, Renal Impairment]. Compared to non-HCV infected subjects with normal renal function [creatinine clearance (CrCl) of 90 mL/min, defined using the Cockcroft-Gault CrCl formula], the AUC of daclatasvir was estimated to be 26.4%, 59.8%, and 79.6% higher in subjects with CrCl values of 60, 30, and 15 mL/min, respectively. Daclatasvir unbound AUC was estimated to be 18.0%, 39.2%, and 51.2% higher for subjects with CrCl values of 60, 30, and 15 mL/min, respectively, relative to subjects with normal renal function. Subjects with end-stage renal disease requiring hemodialysis had a 26.9% increase in daclatasvir AUC and a 20.1% increase in unbound AUC compared to subjects with normal renal function. Population pharmacokinetic analysis of data from clinical trials indicated that mild to moderate renal impairment had no clinically meaningful effect on the pharmacokinetics of daclatasvir. Daclatasvir is highly protein bound to plasma proteins and is unlikely to be removed by dialysis.

Elderly Patients

Population pharmacokinetic analysis of data from clinical trials indicated that age had no apparent effect on the pharmacokinetics of daclatasvir.

Paediatric and Adolescent

The pharmacokinetics of daclatasvir in paediatric patients have not been evaluated.

Gender

Population pharmacokinetic analysis of data from clinical trials indicated that gender had no clinically meaningful effect on the pharmacokinetics of daclatasvir.

Race

Population pharmacokinetic analysis of data from clinical trials indicated that race had no clinically meaningful effect on the pharmacokinetics of daclatasvir..

Pharmacodynamics

The effect of daclatasvir 60 mg and 180 mg on the QTc interval was evaluated in a randomized, partially blinded, placebo-controlled, positive-controlled thorough QT study in 56 healthy subjects. Single doses of 60 mg or 180 mg daclatasvir did not have a clinically relevant effect on QTc interval as corrected by Fridericia's method (QTcF). There was no significant relationship between increased daclatasvir plasma concentration and change in QTc. A daclatasvir dose of 180 mg is expected to bracket the highest plasma concentrations expected clinically.

CLINICAL TRIALS

The efficacy of DAKLINZA in combination with another oral agent has been evaluated in six phase 2/3 studies, in combination with SUNVEPRA (HALLMARK DUAL and HALLMARK NIPPON) and in combination with sofosbuvir, with or without ribavirin (studies AI444040, ALLY-3 (AI444218), ALLY-2 (AI444216) and ALLY-1 (AI444215)). The efficacy and safety of DAKLINZA in combination with SUNVEPRA, peginterferon alfa, and ribavirin was evaluated in the phase 3 HALLMARK QUAD trial. HCV RNA values were measured during the clinical trials using the COBAS TaqMan HCV test (version 2.0), for use with the High Pure System. The assay had a lower limit of quantification (LLOQ) of 25 IU per mL except in the HALLMARK NIPPON study, where the LLOQ was 15 IU per mL. SVR (virologic cure) was defined as HCV RNA below the lower limit of quantitation (LLOQ) at post-treatment Week 12.

DAKLINZA in Combination with Sofosbuvir

The efficacy and safety of DAKLINZA in combination with sofosbuvir in the treatment of patients with HCV infection were evaluated in four open-label randomized studies (AI444040, ALLY-3, ALLY-2 and ALLY-1).

Study AI444040

In Study AI444040, 211 adults with HCV genotype 1, 2 or 3 infection and without cirrhosis received daclatasvir and sofosbuvir, with or without ribavirin. Among the 167 subjects with HCV genotype 1 infection, 126 were treatment naive and 41 had failed prior therapy with a protease inhibitor (PI) regimen (boceprevir or telaprevir). All 44 subjects with HCV genotype 2 or 3 infection were treatment-naive. The dose of DAKLINZA was 60 mg once daily and the dose of sofosbuvir was 400 mg once daily. Treatment duration was 12 weeks for 82 treatment-naive HCV genotype 1 subjects, and 24 weeks for the other 129 subjects (treatment-naive HCV genotype 1, 2, or 3 and genotype 1 subjects who had failed prior PI therapy). All subjects were followed for 48 weeks post-treatment. Among the 211 subjects, median age was 54 years (range: 20 to 70); 83% were white, 12% were black, 2% were Asian; and 20% were Hispanic or Latino. The mean score on the FibroTest (a validated non-invasive diagnostic assay for liver fibrosis status) for all 211 subjects was 0.460 (range: 0.03 to 0.89). Conversion of the FibroTest score to the corresponding METAVIR score suggests that 35% of all subjects (49% of subjects with prior PI failure, 30% of subjects with genotype 2 or 3) had F3 or greater liver fibrosis. Most subjects in this study (71%, including 98% of prior PI failures) had IL-28B rs12979860 non-CC genotypes.

SVR was achieved by 99% of subjects with HCV genotype 1, 96% of those with genotype 2, and 89% of those with genotype 3. Response was rapid (more than 97% of subjects had HCV RNA <LLOQ at Week 4) and was not influenced by HCV subtype (1a/1b), IL28B genotype, or use of ribavirin. Treatment-naïve subjects with HCV genotype 1 who received 12 weeks of treatment had a similar response as those treated for 24 weeks.

While the addition of ribavirin to the regimen did not result in an increase in efficacy, the frequencies of adverse reactions commonly associated with ribavirin therapy (rash, cough, anaemia, dyspnoea, insomnia, and anxiety) were higher for subjects in this study who received ribavirin than for subjects who did not.

SVR12 and outcomes in subjects without SVR in AI444040 are shown by patient population in Tables 3 and 4.

Table 3: Treatment Outcomes, DAKLINZA in Combination with Sofosbuvir with or without Ribavirin in Subjects with HCV Genotype 1 in Study AI444040

	Treatment-naïve			Prior telaprevir or boceprevir failures		
	DAKLINZA + sofosbuvir n=70	DAKLINZA + sofosbuvir + ribavirin n=56	All n=126	DAKLINZA + sofosbuvir n=21	DAKLINZA + sofosbuvir + ribavirin n=20	All n=41
SVR12 (overall) ^{a,b}	100% (70/70)	98% (55/56)	99% (125/126)	100% (21/21)	100% (20/20)	100% (41/41)
≥ F3 liver fibrosis	--	--	100% (41/41)	--	--	100% (20/20)
Outcomes for subjects without SVR						
Virologic breakthrough ^c	0	0	0	0	0	0
Relapse ^c	0	0	0	0	0	0
Missing post-treatment data	0	2% (1/56)	1% (1/126)	0	0	0
Outcomes (SVR) for Subjects with Multiple Baseline Factors						
Metavir F3/F4 fibrosis, IL28B non-C/C, HCV RNA >800,000 IU/mL	100% (17/17)					

^a Missing HCV RNA data were imputed using the NVCB approach.

^b In study AI444040, 31 subjects received a 7 day lead-in with sofosbuvir monotherapy. When these subjects are excluded, SVR rates for treatment naïve subjects with HCV genotype 1 are 99% (110/111).

^c Virologic breakthrough was defined as confirmed increase in viral load of at least 1 log from nadir or any confirmed HCV RNA ≥LLOQ on or after treatment Week 8. Relapse was defined as HCV RNA ≥ LLOQ during follow-up after HCV RNA < LLOQ at end of treatment.

Table 4: Treatment Outcomes, DAKLINZA in Combination with Sofosbuvir with or without Ribavirin for 24 Weeks, Treatment-Naive Patients with HCV Genotype 2 or 3 in Study AI444040

	Genotype 2			Genotype 3		
	DAKLINZA + sofosbuvir n=17	DAKLINZA + sofosbuvir + ribavirin n=9	All Genotype 2 n=26	DAKLINZA + sofosbuvir n=13	DAKLINZA + sofosbuvir + ribavirin n=5	All Genotype 3 n=18
SVR12 ^a	100% (17/17)	89% (8/9)	96% (25/26)	85% (11/13)	100% (5/5)	89% (16/18)
≥ F3 liver fibrosis	--	--	100% (8/8)	--	--	100% (5/5)
Outcomes for subjects without SVR						
Virologic breakthrough ^c	0	0	0	8% (1/13)	0	6% (1/18)
Relapse ^c	0	0	0	9% (1/11)	0	6% (1/16)
Missing post-treatment data	0	11% (1/9)	4% (1/26)	0	0	0
Outcomes (SVR) for Subjects with Multiple Baseline Factors						
Metavir F3/F4 fibrosis, IL28B non-C/C, HCV RNA >800,000 IU/mL			100% (1/1)			0

^a Missing HCV RNA data were imputed using the NVCB approach.

^b In study AI444040, 31 subjects received a 7 day lead-in with sofosbuvir monotherapy. When these subjects are excluded, SVR rates are 94% (16/17) in subjects with HCV genotype 2 and 100% (11/11) in subjects with HCV genotype 3.

^c Virologic breakthrough was defined as confirmed increase in viral load of at least 1 log from nadir or any confirmed HCV RNA ≥LLOQ on or after treatment Week 8. Relapse was defined as HCV RNA ≥ LLOQ during follow-up after HCV RNA < LLOQ at end of treatment.

Study ALLY-3

Study ALLY-3 was a confirmatory phase 3 study in which the combination of daclatasvir and sofosbuvir administered for 12 weeks was evaluated in 152 adults infected with HCV genotype 3; 101 patients were treatment-naïve and 51 patients had failed prior antiviral therapy, including 7 patients who had received sofosbuvir and ribavirin. Median age was 55 years (range: 24 to 73); 90% of patients were white; 4% were black/African-American; 5% were Asian; 16% were Hispanic or Latino. Most patients (71%) had a high baseline viral load (HCV RNA level ≥800,000 IU/mL). Twenty-one percent of patients had compensated cirrhosis. Most patients (61%) had IL-28B rs12979860 non-CC genotypes.

SVR12 was achieved by 90% of treatment-naïve patients and 86% of treatment-experienced patients. Response was rapid (viral load at Week 4 showed that more than 95% of patients responded to therapy) and was not influenced by IL28B genotype. SVR12 rates were lower among patients with cirrhosis (see Table 5).

Table 5: Treatment outcomes, daclatasvir in combination with sofosbuvir for 12 weeks, patients with HCV genotype 3^a in Study ALLY-3

	Treatment-naïve N=101	Treatment- experienced^b N=51	Total N=152
End of treatment response (HCV RNA undetectable)	99% (100/101)	100% (51/51)	99% (151/152)
SVR12 ^c	90% (91/101)	86% (44/51)	89% (135/152)
No cirrhosis ^d	97% (73/75)	94% (32/34)	96% (105/109)
With cirrhosis ^d	58% (11/19)	69% (9/13)	63% (20/32)
Virologic failure^e			
Virologic breakthrough	0	0	0
Relapse	9% (9/100)	14% (7/51)	11% (16/151)

^a All patients had HCV genotype 3a infection.

^b Most of the treatment-experienced patients had received interferon-based therapy, but 7 patients received sofosbuvir + ribavirin and 2 patients received a cyclophilin inhibitor.

^c Patients who had missing data at follow-up Week 12 were considered responders if their next available HCV RNA value was <LLOQ.

^d Cirrhosis was determined by liver biopsy (METAVIR F4) for 14 patients, FibroScan >14.6 kPa for 11 patients or FibroTest score ≥0.75 and aspartate aminotransferase (AST): platelet ratio index (APRI) >2 for 7 patients. For 11 patients, cirrhosis status was missing or inconclusive (FibroTest score >0.48 to <0.75 or APRI >1 to ≤2). See PHARMACOLOGY, [Resistance in Clinical Studies](#), for SVR rates by presence or absence of baseline polymorphisms.

^e One treatment-naïve patient with cirrhosis had detectable HCV RNA at end of treatment. Relapse was defined as confirmed HCV RNA ≥LLOQ during follow-up after HCV RNA undetectable at end of treatment.

Study ALLY-2

In study ALLY-2, the combination of daclatasvir and sofosbuvir administered for 12 weeks was evaluated in 153 adults with chronic hepatitis C and HIV co-infection; 101 patients were HCV treatment-naïve and 52 patients had failed prior HCV therapy. Patients with HCV genotype 1, 2, 3, 4, 5, or 6 infection were eligible to enroll, however no patients with genotype 5 or 6 were enrolled. Sixty-eight percent of patients had HCV genotype 1a, 15% had HCV genotype 1b, 8% had genotype 2, 7% had genotype 3, and 2% had genotype 4. The dose of daclatasvir was adjusted for concomitant antiretroviral use. Median age was 53 years (range: 24 to 71); 63% of patients were white; 33% were

black/African-American; 1% were Asian; 18% of patients were Hispanic/Latino. Most patients (80%) had a high baseline viral load (HCV RNA level $\geq 800,000$ IU/mL). Sixteen percent of patients had compensated cirrhosis. Most patients (73%) had IL-28B rs12979860 non-CC genotypes. Concomitant HIV therapy included PI-based regimens (darunavir + ritonavir, atazanavir + ritonavir, or lopinavir/ritonavir) for 46% of patients, NNRTI-based (efavirenz, nevirapine, or rilpivirine) regimens for 26%; 27% of patients were receiving other HIV therapy, most commonly integrase-based (raltegravir or dolutegravir) regimens. Two patients were not receiving treatment for HIV.

The SVR12 rate for the primary endpoint in treatment naive genotype 1 patients was achieved by 96% (80/83) of patients administered daclatasvir and sofosbuvir for 12 weeks in ALLY-2. SVR rates were high regardless of combination antiretroviral therapy (CART). Among treatment-naive patients, 98% (46/47) of those receiving a PI-based regimen, 100% (28/28) of those receiving an NNRTI regimen, and 92% (23/25) of those receiving another CART regimen achieved SVR. Among treatment-experienced patients, 96% (22/23) of those receiving a PI-based regimen, 100% (12/12) of those receiving an NNRTI regimen, and 100% (16/16) of those receiving another CART regimen achieved SVR. SVR rates were comparable regardless of age, race, gender, IL28B allele status, or baseline HCV RNA level. Outcomes by prior treatment experience are presented in Table 6.

Table 6: Treatment outcomes, daclatasvir in combination with sofosbuvir for 12 weeks, patients with HCV/HIV co-infection in Study ALLY-2

	HCV Treatment-naïve N=101	HCV Treatment-experienced* N=52
End of treatment response(HCV RNA undetectable)	99% (100/101)	100% (52/52)
SVR12**	97% (98/101)	98% (51/52)
No cirrhosis***	98% (88/90)	100% (34/34)
With cirrhosis***	89% (8/9)	93% (14/15)
Genotype 1 [‡]	96% (80/83)	98% (43/44)
Genotype 2	100% (11/11)	100% (2/2)
Genotype 3	100% (6/6)	100% (4/4)
Genotype 4	100% (1/1)	100% (2/2)
Virologic failure		
Detectable HCV RNA at end of treatment	1% (1/101)	0
Relapse ^{‡‡}	1% (1/100)	2% (1/52)
Missing post-treatment data	1% (1/100)	0

* Most of the HCV treatment-experienced patients had received interferon-based therapy with or without NS3/4 PI add-on therapy; 3 patients received sofosbuvir + ribavirin.

** Patients who had missing data at follow-up Week 12 were considered responders if their next available HCV RNA value was <LLOQ.

*** Cirrhosis was determined by liver biopsy, FibroScan >14.6 kPa, or FibroTest score ≥ 0.75 and aspartate aminotransferase (AST): platelet ratio index (APRI) >2. For 5 patients, cirrhosis status was indeterminate.

‡ Genotype 1a: 96% (68/71) for treatment naive and 97% (32/33) for treatment experienced. Genotype 1b: 100% for both treatment naive (12/12) and treatment experienced (11/11).

‡‡ Relapse was defined as confirmed HCV RNA \geq LLOQ during follow-up after HCV RNA undetectable at end of treatment.

Study ALLY-1

In study ALLY-1, the regimen of daclatasvir, sofosbuvir, and ribavirin administered for 12 weeks was evaluated in 113 adults with chronic hepatitis C and Child-Pugh A, B or C cirrhosis (n=60) or HCV recurrence after liver transplant (n=53). Patients with HCV genotype 1, 2, 3, 4, 5 or 6 infection were eligible to enroll; however, no patients with genotype 5 were enrolled. Fifty-eight percent of patients had HCV genotype 1a, 19% had HCV genotype 1b, 4% had genotype 2, 15% had genotype 3, 4% had genotype 4, and 1% had genotype 6. Patients received daclatasvir 60 mg once daily, sofosbuvir 400 mg once daily, and ribavirin for 12 weeks and were monitored for 24 weeks post treatment.

Patients in ALLY-1 had a median age of 59 years (range: 19 to 82); 96% of patients were white, 4% were black/African-American, and 1% were Asian; 34% of patients were Hispanic/Latino. Most patients (59%) were treatment-experienced, and most (71%) had baseline HCV RNA levels greater than or equal to 800,000 IU/mL. Among the 60 patients in the cirrhosis cohort, 20% were Child-Pugh class A, 53% were Child-Pugh class B, and 27% were Child-Pugh class C. Most (55%) of the 53 patients in the post-liver transplant cohort had F3 or F4 fibrosis (based on FibroTest results). Most patients (77%) had IL-28B rs12979860 non-CC genotypes.

SVR12 rates for the co-primary endpoints were 82% (37/42) in genotype 1 patients in the cirrhosis cohort and 95%(39/41) in genotype 1 patients in the post-liver transplant cohort (Table 7). SVR rates were comparable regardless of age, race, gender, IL28B allele status, or baseline HCV RNA level. In the cirrhosis cohort, 4 patients with hepatocellular carcinoma underwent liver transplantation after 1–71 days of treatment; 3 of the 4 patients received 12 weeks of post-liver transplant treatment extension and 1 patient, treated for 23 days before transplantation, did not receive treatment extension. All 4 patients achieved SVR12.

Table 7: Treatment outcomes, daclatasvir in combination with sofosbuvir and ribavirin for 12 weeks, patients with cirrhosis or HCV recurrence after liver transplant, Study ALLY-1

	Child-Pugh A, B, or C Cirrhosis N=60	Post LiverTransplant N=53
End of treatment response (HCV RNA undetectable)	97% (58/60)	100% (53/53)
SVR12*	83% (50/60)	94% (50/53)
	Child-Pugh A: 92% (11/12)	
	Child-Pugh B: 94% (30/32)	
	Child-Pugh C: 56% (9/16)	

Table 7: Treatment outcomes, daclatasvir in combination with sofosbuvir and ribavirin for 12 weeks, patients with cirrhosis or HCV recurrence after liver transplant, Study ALLY-1

	Child-Pugh A, B, or C Cirrhosis N=60	Post Liver Transplant N=53
Genotype 1**	82% (37/45)	95% (39/41)
Genotype 2	80% (4/5)	--
Genotype 3	83% (5/6)	91% (10/11)
Genotype 4	100% (4/4)	--
Genotype 6	--	100% (1/1)
Virologic failure		
Detectable HCV RNA at end of treatment	2% (1/60)	0
Relapse [‡]	16% (9/58)	6% (3/53)

* Patients who had missing data at follow-up Week 12 were considered responders if their next available HCV RNA value was <LLOQ.

** Among patients with HCV genotype 1, 91% (10/11) patients with Child-Pugh A, 92% (22/24) patients with Child-Pugh B, and 50% (5/10) of patients with Child-Pugh C achieved SVR.

Among patients with cirrhosis, 77% (26/34) of those with genotype 1a and 100% (11/11) of those with genotype 1b achieved SVR; among post-liver transplant patients, 97% (30/31) of those with genotype 1a and 90% (9/10) of those with genotype 1b achieved SVR.

‡ Relapse was defined as confirmed HCV RNA \geq LLOQ during follow-up after HCV RNA undetectable at end of treatment.

DAKLINZA in Combination with SUNVEPRA in Subjects with HCV Genotype 1b

HALLMARK DUAL (Study AI447028) was a global open-label study that included subjects with chronic HCV genotype 1b infection and compensated liver disease who were treatment naive, null or partial responders to peginterferon alfa and ribavirin, or were intolerant of or ineligible to receive interferon-based therapy. Subjects in the treatment-naive cohort were randomized 2:1 to receive DAKLINZA 60 mg once daily in combination with SUNVEPRA 100 mg twice daily for 24 weeks or placebo for 12 weeks (placebo subjects were rolled over into another study and offered treatment with DAKLINZA in combination with SUNVEPRA for 24 weeks). Subjects in the null or partial responder and intolerant/ineligible cohorts were treated with DAKLINZA 60 mg once daily in combination with SUNVEPRA 100 mg twice daily for 24 weeks. Subjects were monitored for 24 weeks post treatment.

Of the 745 treated subjects, in HALLMARK DUAL included in the efficacy analyses, 643 subjects received DAKLINZA in combination with SUNVEPRA. These 643 subjects had a median age of 57 years (range: 20 to 79); 48% of the subjects were male; 70% were white, 24% were Asian, 5% were black, and 4% were Hispanic/Latino. The mean baseline HCV RNA level was 6.4 log₁₀ IU/mL; 32% of the subjects had compensated cirrhosis (Child-Pugh A) and 29% had the IL28B CC genotype. Baseline characteristics of the 102 placebo-treated subjects were similar to those of subjects treated with DAKLINZA in combination with SUNVEPRA.

SVR, the primary endpoint, and outcomes in subjects without SVR in HALLMARK DUAL are shown by patient population in Table 8. SVR rates for patients with and without baseline NS5A resistance associated polymorphisms are included in the table.

Table 8: Treatment Outcomes in HALLMARK DUAL, DAKLINZA in Combination with SUNVEPRA in Subjects with HCV Genotype 1b Infection

Treatment outcomes	Treatment-Naive n=203	Failed Prior Therapy All (Partial and Null Responders) n=205	Interferon Intolerant/ Ineligible n=235
SVR12^a			
All	91% (184/203)	82% (169/205)	83% (194/235)
With Y93H or L31F/I/M/V ^b	59% (10/17)	28% (7/25)	37% (11/30)
Without Y93H or L31F/I/M/V	96% (162/169)	92% (151/165)	90% (172/191)
With cirrhosis	91% (29/32)	87% (55/63)	81% (90/111)
No cirrhosis	91% (155/171)	80% (114/142)	84% (104/124)
Outcomes for subjects without SVR			
On-treatment virologic failure ^c	6% (12/203)	14% (29/205)	12% (28/235)
Relapse ^d	3% (5/189)	4% (7/174)	6% (12/204)
Missing post-treatment data	1% (2/203)	0	<1% (1/235)

^a Missing HCV RNA data at follow-up week 12 were imputed using the Next Value Carried Backwards (NVCB) approach, i.e., using the next and closest available HCV RNA measurement after the follow-up week 12 HCV RNA visit window.

^b Analysis includes patients with available baseline NS5A sequence data.

^c On-treatment virologic failure includes subjects with virologic breakthrough (confirmed >1 log₁₀ IU/mL increase in HCV RNA from nadir or any confirmed HCV RNA ≥LLOQ after <LLOQ during treatment), those with HCV RNA ≥LLOQ at treatment Week 8, and those with detectable HCV RNA at end of treatment.

^d Relapse rates are calculated with a denominator of subjects with undetectable HCV RNA at the end of treatment.

Among subjects who had failed prior therapy, SVR rate was the same (82%) among the 84 subjects with prior partial response and the 119 subjects with prior null response. Response was rapid (95% of subjects had HCV RNA <LLOQ at Week 4). There were no differences in antiviral response due to race, gender, IL28B allele, presence or absence of cirrhosis, or age in any of the treatment populations. SVR rates were consistently high across all categories of baseline viral load. Among subjects 65 and older, 88% (117/133) achieved SVR and among subjects 75 years or older, 100% (10/10) achieved SVR.

HALLMARK NIPPON (Study AI447026) was an open-label study that included Japanese subjects with HCV genotype 1b infection and compensated liver disease who were nonresponders (null or partial responders) to interferon alfa or beta and ribavirin or who were intolerant of or ineligible to receive interferon-based therapy. Subjects in both the nonresponder and intolerant/ineligible cohorts were treated with DAKLINZA 60 mg once

daily in combination with SUNVEPRA 100 mg twice daily for 24 weeks and monitored for 24 weeks post-treatment.

The 222 treated subjects in HALLMARK NIPPON had a median age of 63 years (range: 24-75); 35% of the subjects were male. Mean baseline HCV RNA level was 7 log₁₀ IU/mL, and 10% of subjects had compensated cirrhosis (Child-Pugh A). Among 87 subjects in the nonresponder cohort, 36 subjects were prior partial responders and 48 subjects were prior null responders to interferon/ribavirin. Among 135 subjects in the interferon intolerant/ineligible cohort, 35 subjects were in the intolerant category and 100 in the ineligible. Most of the nonresponder cohort had a non-CC IL28B genotype, while most of the intolerant/ineligible cohort had IL28B genotype CC.

SVR and outcomes for subjects without SVR in HALLMARK NIPPON are shown by patient population in Table 9. SVR rates for patients with and without baseline NS5A resistance associated polymorphisms are included in the table.

Table 9: Treatment Outcomes in HALLMARK NIPPON, DAKLINZA in Combination with SUNVEPRA in Subjects with HCV Genotype 1b Infection

Treatment outcomes	Failed Prior Therapy (Partial and Null) n=87	Interferon Intolerant/Ineligible n=135
SVR12^a		
All	81% (70/87)	88% (119/135)
With Y93H or L31F/I/M/V ^b	29% (4/14)	54% (13/24)
Without Y93H or L31F/I/M/V	90% (65/72)	96% (100/104)
With cirrhosis	91% (10/11)	91% (10/11)
No cirrhosis	79% (60/76)	88% (109/124)
Outcomes for subjects without SVR		
On-treatment virologic failure ^c	13% (11/87)	4% (6/135)
Relapse ^d	8% (6/76)	8% (10/129)

^a Missing HCV RNA data were imputed using the NVCB approach.

^b Analysis includes patients with available baseline NS5A sequence data.

^c On-treatment virologic failure includes subjects with virologic breakthrough (confirmed >1 log₁₀ IU/mL increase in HCV RNA from nadir or any confirmed HCV RNA ≥LLOQ after <LLOQ during treatment), those with confirmed HCV RNA ≥LLOQ on or after treatment Week 8, and those with detectable HCV RNA at end of treatment.

^d Relapse rates are calculated with a denominator of subjects with undetectable HCV RNA at the end of treatment.

In the nonresponder cohort, 78% of prior partial responders and 81% of prior null responders achieved SVR. In the intolerant/ineligible cohort, 94% of subjects who were intolerant and 86% of those who were ineligible achieved SVR. Response was rapid (96% of subjects had HCV RNA <LLOQ at Week 4). Within the prior nonresponder and interferon intolerant/ineligible populations, there were no differences in antiviral response due to gender, baseline HCV RNA level, IL28B allele, presence or absence of cirrhosis or age. Among subjects 65 years and older, 91% (81/89) achieved SVR and among subjects 75 years or older, 100% (4/4) achieved SVR.

DAKLINZA in Combination with SUNVEPRA in Subjects with HCV Genotype 1a

The efficacy of DAKLINZA and SUNVEPRA combination therapy in the treatment of chronic hepatitis C genotype 1a infection has not been established. In a study of DAKLINZA and SUNVEPRA combination therapy for 24 weeks in subjects with chronic HCV genotype 1 infection who were prior null responders to peginterferon alfa plus ribavirin, 2 (22%) of the 9 subjects with HCV genotype 1a infection had undetectable HCV RNA at post-treatment week 24.

DAKLINZA in Combination with SUNVEPRA, Peginterferon Alfa, and Ribavirin in Subjects with HCV Genotype 1 or 4

The efficacy and safety of DAKLINZA in combination with SUNVEPRA, peginterferon alfa, and ribavirin in the treatment of chronic HCV genotype 1 or 4 infection were evaluated in the single-arm, open-label phase 3 HALLMARK QUAD study (AI447029) in adults with compensated liver disease who were partial or null responders to therapy with peginterferon alfa 2a or 2b and ribavirin. Subjects received DAKLINZA 60 mg once daily, SUNVEPRA 100 mg twice daily, peginterferon alfa-2a 180 µg subcutaneously once weekly, and ribavirin 1000 mg per day (body weight less than 75 kg) or 1200 mg per day (at least 75 kg) in two divided doses for 24 weeks followed by 24 weeks of follow-up after completion of treatment or early discontinuation.

The 398 treated subjects in HALLMARK QUAD had a median age of 53 years (range: 19-76); 69% of the subjects were male; 76% were white, 12% were Asian, 9% were black; 9% were Hispanic/Latino. The mean baseline HCV RNA level was 6.46 log₁₀ IU/mL; 23% of subjects had compensated cirrhosis (Child-Pugh A); 89% had HCV genotype 1 and 11% had HCV genotype 4; 91% of subjects had non-CC IL28B genotype.

SVR, the primary endpoint, and outcomes in subjects without SVR in HALLMARK QUAD are shown by patient population in Table 10. The demonstrated effectiveness of DAKLINZA/SUNVEPRA/peginterferon alfa/ribavirin treatment in HCV genotype 1 and 4 null responders indicates that this regimen is also expected to be effective in HCV genotype 1 and 4 subjects who are treatment-naive.

Table 10: Treatment Outcomes in HALLMARK QUAD, DAKLINZA in Combination with SUNVEPRA, Peginterferon alfa, and Ribavirin in Subjects with HCV Genotype 1 or 4

Treatment outcomes	HCV Genotype 1 n=354	HCV Genotype 4 n=44
SVR12^a		
All	93% (330/354)	100% (44/44)
Prior partial responders	93% (111/120)	100% (10/10)
Prior null responders	94% (219/234)	100% (34/34)
With cirrhosis	90% (66/73)	100% (20/20)
No cirrhosis	94% (264/281)	100% (24/24)

Treatment outcomes	HCV Genotype 1 n=354	HCV Genotype 4 n=44
Outcomes for subjects without SVR		
On-treatment virologic failure ^b	3% (12/354)	0/44
Relapse ^c	2% (8/337)	0/43
Missing post-treatment data	1% (4/354)	0/44

^a Missing HCV RNA data were imputed using the NVCB approach.

^b On-treatment virologic failure includes subjects with virologic breakthrough (confirmed > 1 log₁₀ increase in HCV RNA over nadir or any confirmed HCV RNA ≥LLOQ after confirmed undetectable), those with confirmed HCV RNA ≥LLOQ on or after treatment Week 8, and those with detectable HCV RNA at end of treatment.

^c Relapse rates are calculated with a denominator of subjects with undetectable HCV RNA at the end of treatment.

Response was rapid (98% of subjects had HCV RNA <LLOQ at Week 4). There were no differences in antiviral response due to gender, age, baseline HCV RNA level, presence or absence of baseline polymorphisms, IL28B allele status, or presence or absence of cirrhosis in any of the treatment populations.

Long-term Follow-up

Limited data are available from an ongoing follow-up study to assess durability of response up to 3 years after treatment with DAKLINZA. Among 224 subjects who achieved SVR12 with DAKLINZA and SUNVEPRA with a median duration of post-SVR12 follow-up of approximately 8.5 months, 1 (<1%) relapse occurred. No relapses occurred among 28 subjects who achieved SVR12 with DAKLINZA and sofosbuvir (± ribavirin) with a median duration of post-SVR12 follow-up of approximately 14.5 months or among 30 subjects who achieved SVR12 with DAKLINZA, SUNVEPRA, peginterferon alfa, and ribavirin with a median duration of post-SVR12 follow-up of approximately 18 months.

INDICATIONS

DAKLINZA is indicated in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults [see CLINICAL TRIALS and DOSAGE AND ADMINISTRATION].

CONTRAINDICATIONS

- DAKLINZA is contraindicated in patients with previously demonstrated hypersensitivity to daclatasvir or any component of the product.
- Since DAKLINZA is used in combination with other medicinal products, the contraindications applicable to those medicinal products are applicable to the combination regimen. Refer to the respective product information for a list of contraindications.

- The combination of DAKLINZA with peginterferon alfa and ribavirin is contraindicated in women who are pregnant or may become pregnant and men whose female partners are pregnant because of the risks of birth defects and foetal death associated with ribavirin [see PRECAUTIONS].
- DAKLINZA is contraindicated in combination with drugs that strongly induce CYP3A4 and thus may lead to lower exposure and loss of efficacy of DAKLINZA. Contraindicated drugs include, but are not limited to, phenytoin, carbamazepine, oxcarbazepine, phenobarbital, rifampicin, rifabutin, dexamethasone and St John's wort (*Hypericum perforatum*) [see INTERACTIONS WITH OTHER MEDICINES].

PRECAUTIONS

General

DAKLINZA must not be administered as monotherapy. DAKLINZA must be administered in combination with other medicinal products for the treatment of chronic HCV infection [see INDICATIONS, CLINICAL TRIALS and DOSAGE AND ADMINISTRATION]. Warnings and precautions for other medicinal products in the regimen also apply when coadministered with DAKLINZA.

Potential for hepatotoxicity with SUNVEPRA-containing regimens

Drug-induced liver injury, in some cases severe, has been observed with SUNVEPRA-containing regimens. **See prescribing information for SUNVEPRA for hepatic monitoring recommendations.**

In DAKLINZA regimens that did not contain SUNVEPRA, the frequencies of clinically significant ALT or AST elevations were similar to frequencies among patients who received placebo.

Potential for drug interaction with amiodarone

Severe bradycardia and heart block have been reported in patients receiving amiodarone with DAKLINZA and sofosbuvir, with or without other medicinal products that lower heart rate. Bradycardia has generally occurred within hours to days. Bradycardia generally resolved after discontinuation of HCV treatment. The mechanism for the bradycardia effect has not been established.

Amiodarone should be coadministered with DAKLINZA and sofosbuvir only if alternative antiarrhythmic treatments are contraindicated or not tolerated. For patients with no alternative treatment options, close monitoring is recommended. Patients should be continuously monitored in an inpatient setting for the first 48 hours of coadministration, after which outpatient monitoring or self-monitoring of the heart rate should occur on a daily basis through at least the first two weeks of treatment.

Due to the long half life of amiodarone, patients who have discontinued amiodarone just before starting DAKLINZA and sofosbuvir should also undergo cardiac monitoring as described above.

All patients receiving DAKLINZA and sofosbuvir in combination with amiodarone should be warned of the symptoms of bradycardia and heart block and advised to seek medical advice urgently should they experience them.

Refer to the amiodarone and sofosbuvir product information. (See INTERACTIONS WITH OTHER MEDICINES and ADVERSE EFFECTS - Postmarketing experience.)

Hepatitis B Virus (HBV) Reactivation

Cases of hepatitis B virus (HBV) reactivation, including fatal cases, have been reported during and after treatment of HCV with direct-acting antiviral agents in HCV/HBV co-infected patients. Screening for current or past HBV infection, including testing for HBV surface antigen (HBsAg) and HBV core antibody (anti-HBc), should be performed in all patients before initiation of treatment with DAKLINZA.

Patients with serologic evidence of current or past HBV infection should be monitored and treated according to current clinical practice guidelines to manage potential HBV reactivation. Consider initiation of HBV antiviral therapy, if indicated.

Genotype-specific activity

The clinical data to support the use of DAKLINZA and sofosbuvir in patients infected with HCV genotypes 2, 4, 5 and 6 are limited.

Hepatic Impairment and Cirrhosis

No dose adjustment of DAKLINZA is required for patients with mild (Child-Pugh A), moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment [see PHARMACOLOGY - Special Populations and CLINICAL TRIALS].

Co-infection with Hepatitis B Virus (HBV)

The safety and efficacy of DAKLINZA in the treatment of chronic HCV infection in patients who are co-infected with HBV have not been established (see PRECAUTIONS - Hepatitis B Virus (HBV) Reactivation).

Renal Impairment

No dose adjustment of DAKLINZA is required for patients with any degree of renal impairment [see PHARMACOLOGY - Special Populations].

Retreatment with DAKLINZA

The efficacy of DAKLINZA as part of a retreatment regimen in patients with prior exposure to a NS5A inhibitor has not been established.

Effects on Fertility

Daclatasvir alone had no effects on fertility in male or female rats. The highest AUC value in unaffected females was 18-fold the exposure at the recommended human dose. In male rats, effects on reproductive endpoints were limited to reduced prostate/seminal vesicle weights, and minimally increased dysmorphic sperm at 200 mg/kg/day (19-fold the exposure at the recommended human daily clinical dose); however, neither finding adversely affected fertility or the number of viable conceptuses sired.

Use with ribavirin and Peginterferon alfa: Ribavirin caused reversible testicular toxicity in animals; while peginterferon alfa may impair fertility in females. Please refer to Product Information for ribavirin and peginterferon alfa for additional information.

Use in Pregnancy

Use of DAKLINZA with Peginterferon Alfa and Ribavirin (Pregnancy Category X):

Ribavirin may cause birth defects and/or death of the exposed fetus and animal studies have shown that interferons have abortifacient effects. Significant teratogenic and/or embryocidal effects have been demonstrated in all animal species exposed to ribavirin; and

therefore ribavirin is contraindicated in women who are pregnant and in the male partners of women who are pregnant [see CONTRAINDICATIONS and PRECAUTIONS, and ribavirin prescribing information]. Interferons have abortifacient effects in animals and should be assumed to have abortifacient potential in humans. Refer also to the product information for peginterferon alfa and ribavirin.

Extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients. Ribavirin therapy should not be started unless a report of a negative pregnancy test has been obtained immediately prior to initiation of therapy.

When DAKLINZA is used in combination with peginterferon alfa and ribavirin, women of childbearing potential and their male partners must use two forms of effective contraception during treatment and for at least 6 months after treatment has concluded.

DAKLINZA (Pregnancy Category B3)

There are no adequate and well-controlled studies in pregnant women. Studies of daclatasvir in animals have shown both maternal and embryofetal developmental toxicity at AUC levels above the recommended human dose (RHD). DAKLINZA should not be used during pregnancy or in women of childbearing potential not using contraception. Use of effective contraception should be continued for 5 weeks after completion of treatment.

Daclatasvir crosses the placenta in rats. Embryofetal development studies in rats and rabbits showed embryolethality, reduced fetal bodyweights, and fetal malformations at doses which were maternotoxic (mortality, adverse clinical signs, decreases in body weight and food consumption). Fetal malformations in rats included small and misshapen cerebrum, dilated cerebral ventricles, shortened lower jaws, incomplete ossification of parietals and frontals, enlarged fontanels, misshapen and/or fused sternbrae, and supernumerary hindlimb phalanges, at 25 times the RHD AUC. Additional malformations at the high-dose were absent or small or malpositioned eyes, dilated olfactory bulbs, imperforate or absent nasal openings, exencephaly, cleft lip and palate, polydactyly of fore- and hindlimbs, shortened upper jaw, misshapen tympanic annuli, fused nasals and premaxillae, and alterations to the pectoral girdle, sternbrae, vertebrae and ribs, at 52 times the RHD AUC. Fetal malformations in rabbits involved the ribs, and variations were increased in the head and skull, at 72 times the RHD AUC. At the respective NOAELs for both fetal and maternal toxicity, the daclatasvir AUC was 4 times (rats) and 16 times (rabbits) the RHD AUC. In a study of pre- and postnatal development in rats, there was neither maternal nor developmental toxicity at doses up to 50 mg/kg/day, associated with AUC values 2.6-fold the RHD AUC. At the highest dose tested (100 mg/kg/day), maternal toxicity included mortality and dystocia; developmental toxicity included slight reductions in offspring viability in the peri- and neonatal periods; and reductions in birth weight that persisted into adulthood. The AUC value associated with this dose is 4.7-fold the RHD AUC.

Use in lactation

Treatment of rats with daclatasvir during pregnancy and lactation caused decreased pup body weight gain (see Use in Pregnancy).

It is not known whether daclatasvir is excreted in human milk. Daclatasvir was excreted into the milk of lactating rats with concentrations 1.7- to 2-fold maternal plasma levels. Mothers should be instructed not to breastfeed if they are taking DAKLINZA. See also the product information for ribavirin and peginterferon alfa.

Paediatric use

Safety and effectiveness of DAKLINZA in paediatric patients less than 18 years of age have not been established.

Use in elderly

Of more than 2000 subjects in clinical studies of DAKLINZA combination therapy, 310 were 65 years and older and 20 were 75 years and older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects. No dose adjustment of DAKLINZA is required for elderly patients.

Genotoxicity

Daclatasvir was not mutagenic or clastogenic in an in vitro mutagenesis (Ames bacterial mutagenicity) assay, a chromosome aberration assay in Chinese hamster ovary cells, or in an in vivo oral micronucleus study in rats.

See also the product information for ribavirin and peginterferon alfa.

Carcinogenicity

Daclatasvir was not carcinogenic in mice or rats at AUC values 8.7- and 4.7-fold the human exposure at the recommended daily human clinical dose of 60 mg/day, respectively.

See also the product information for ribavirin and peginterferon alfa.

INTERACTIONS WITH OTHER MEDICINES

Potential for Other Medicines to Affect DAKLINZA

Daclatasvir is a substrate of CYP3A4. Therefore, moderate or strong inducers of CYP3A4 may decrease the plasma levels and therapeutic effect of daclatasvir. See CONTRAINDICATIONS for drugs that are contraindicated for use with DAKLINZA due to potential loss of virologic activity.

Strong inhibitors of CYP3A4 may increase the plasma levels of daclatasvir [see DOSAGE AND ADMINISTRATION and Table 11]. Daclatasvir is also a substrate of P-glycoprotein transporter (P-gp) and organic cation transporter (OCT) 1, but coadministration of agents that modify P-gp or OCT-1 activity alone (without concurrent effect on CYP3A4) is unlikely to have a clinically meaningful effect on daclatasvir exposure.

Potential for DAKLINZA to Affect Other Medicines

Daclatasvir is an inhibitor of P-glycoprotein transporter (P-gp), organic anion transporting polypeptide (OATP) 1B1 and 1B3, OCT-1 and breast cancer resistance protein (BCRP). Administration of DAKLINZA may increase systemic exposure to medicinal products that are substrates of P-gp, OATP 1B1 or 1B3, OCT-1, or BCRP, which could increase or prolong their therapeutic effect and adverse reactions. Caution should be used if the medicinal product has a narrow therapeutic range.

Established and Potentially Significant Drug Interactions

Refer to the respective product information for other medicinal products in the regimen for drug interaction information. The most conservative recommendation should be followed.

Table 11 provides clinical recommendations for established or potentially significant drug interactions between DAKLINZA and other drugs. Clinically relevant increase in concentration is indicated as “↑” and clinically relevant decrease as “↓”.

Table 11: Established and Other Potentially Significant Drug Interactions

Concomitant Drug Class: Drug Name	Effect on Concentration^a	Clinical Comment
<i>Antibacterials</i>		
Clarithromycin	Interaction not studied. <i>Expected due to CYP3A4 inhibition by the antibacterial</i> ↑ Daclatasvir	The dose of DAKLINZA should be reduced to 30 mg once daily when coadministered with clarithromycin or other strong inhibitors of CYP3A4.
Erythromycin	Interaction not studied. <i>Expected due to CYP3A4 inhibition by erythromycin</i> ↑ Daclatasvir	Administration of DAKLINZA with erythromycin may result in increased concentrations of daclatasvir. Caution is advised.
<i>Anticoagulants</i>		
Dabigatran etexilate	Interaction not studied. <i>Expected due to inhibition of P-gp by daclatasvir</i> ↑ Dabigatran etexilate	Close clinical monitoring is recommended when initiating therapy with DAKLINZA in patients receiving dabigatran etexilate or other intestinal P-gp substrates that have a narrow therapeutic range.
<i>HCV antiviral agents</i>		
Boceprevir	Interaction not studied. <i>Expected due to CYP3A4 inhibition by boceprevir</i> ↑ Daclatasvir	The dose of DAKLINZA should be reduced to 30 mg once daily when coadministered with boceprevir or other strong inhibitors of CYP3A4.
Telaprevir	↑ Daclatasvir*	The dose of DAKLINZA should be reduced to 30 mg once daily when coadministered with telaprevir or other strong inhibitors of CYP3A4.
<i>HIV or HBV antiviral agents</i>		
Protease inhibitor: Atazanavir/ritonavir	↑ Daclatasvir*	The dose of DAKLINZA should be reduced to 30 mg once daily when coadministered with atazanavir/ritonavir, atazanavir/cobicistat or other strong inhibitors of CYP3A4.
Atazanavir/cobicistat	Interaction not studied. <i>Expected due to CYP3A4 inhibition by atazanavir/cobicistat</i> ↑ Daclatasvir	
Non-nucleoside reverse transcriptase inhibitor (NNRTI): Efavirenz	↓ Daclatasvir*	The dose of DAKLINZA should be increased to 90 mg once daily when coadministered with efavirenz, etravirine, nevirapine or other moderate inducers of CYP3A4.
Etravirine Nevirapine	Interaction not studied. <i>Expected due to CYP3A4 induction by etravirine or nevirapine</i>	

Integrase inhibitor: Elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate	Interaction not studied for this fixed combination tablet. <i>Expected due to CYP3A4 inhibition by cobicistat</i> ↑ Daclatasvir	The dose of DAKLINZA should be reduced to 30 mg once daily when coadministered with cobicistat or other strong inhibitors of CYP3A4.
<i>Antifungals</i>		
Ketoconazole	↑ Daclatasvir*	The dose of DAKLINZA should be reduced to 30 mg once daily when coadministered with other strong inhibitors of CYP3A4.
Itraconazole Posaconazole Voriconazole	Interaction not studied. <i>Expected due to CYP3A4 inhibition by the antifungal:</i> ↑ Daclatasvir	
Fluconazole	Interaction not studied. <i>Expected due to CYP3A4 inhibition by the antifungal</i> ↑ Daclatasvir	
<i>Cardiovascular agents</i>		
Antiarrhythmic: Digoxin	 ↑ Digoxin*	Digoxin and other P-gp substrates with a narrow therapeutic range should be used with caution when coadministered with DAKLINZA . The lowest dose of digoxin should be initially prescribed. The serum digoxin concentrations should be monitored and used for titration of digoxin dose to obtain the desired clinical effect.
Amiodarone	Interaction not studied.	For patients with no alternative antiarrhythmic option, close monitoring is recommended if amiodarone is administered with DAKLINZA + sofosbuvir. Refer to the amiodarone and sofosbuvir product information. (See PRECAUTIONS and ADVERSE EFFECTS - Postmarketing experience.)
Calcium channel blocker: Diltiazem Verapamil	Interaction not studied. <i>Expected due to CYP3A4 inhibition by the calcium channel blocker</i> ↑ Daclatasvir	Administration of DAKLINZA with diltiazem or verapamil may result in increased concentrations of daclatasvir. Caution is advised.
<i>Lipid lowering agents</i>		
HMG-CoA reductase inhibitor: Rosuvastatin	↑ Rosuvastatin*	Caution should be used if DAKLINZA is coadministered with rosuvastatin or other substrates of OATP1B1, OATP1B3, or BCRP.
Atorvastatin Fluvastatin Simvastatin Pitavastatin Pravastatin	Interaction not studied. <i>Expected due to inhibition of OATP 1B1 and/or BCRP by daclatasvir:</i> ↑ concentration of statin	

* These interactions have been studied.

^a The direction of the arrow (↑ = increase, ↓ = decrease) indicates the direction of the change in pharmacokinetic parameters.

Other Drugs

Based on the results of drug interaction studies, no dose adjustment of DAKLINZA is recommended when DAKLINZA is given with SUNVEPRA, cyclosporin, darunavir/ritonavir, dolutegravir, escitalopram, ethinyloestradiol + levonorgestrel, ethinyloestradiol + norethisterone, famotidine, lopinavir/ritonavir, buprenorphine/naloxone, methadone, midazolam, omeprazole, peginterferon alfa, ribavirin, simeprevir, sofosbuvir, tacrolimus, tenofovir.

No clinically relevant effects on the pharmacokinetics of either medicinal product are expected when DAKLINZA is coadministered with any of the following: PDE-5 inhibitors, medicinal products in the ACE inhibitor class (eg, enalapril), medicinal products in the angiotensin II receptor antagonist class (eg, losartan, irbesartan, olmesartan, candesartan, valsartan), abacavir, alprazolam, azithromycin, ciprofloxacin, darunavir/cobicistat, didanosine, disopyramide, emtricitabine, enfuvirtide, flecainide, lamivudine, maraviroc, mexiletine, mycophenolate mofetil, propafenone, quinidine, raltegravir, rilpivirine, sirolimus, stavudine, triazolam, warfarin, zidovudine or antacids.

ADVERSE EFFECTS

DAKLINZA must be administered with other drugs for the treatment of HCV infection. Refer to their respective product information for their associated adverse reactions.

Clinical Experience

The overall safety profile of DAKLINZA is based on data from 1995 patients with chronic HCV infection who received DAKLINZA once daily in combination with SUNVEPRA (n=918), sofosbuvir with or without ribavirin (n=679, pooled data), or SUNVEPRA, peginterferon alfa, and ribavirin (n=398) in 8 clinical trials. Safety experience is presented by regimen.

All-Oral Regimens

DAKLINZA in combination with sofosbuvir: The safety of DAKLINZA 60 mg once daily in combination with sofosbuvir (with or without ribavirin) was assessed in four open-label randomized clinical trials (AI444040, ALLY-3, ALLY-2 and ALLY-1) in 679 subjects with chronic HCV genotype 1, 2, 3, 4, 5, or 6 infection. Subjects were treated for 12 or 24 weeks.

The most common adverse events (frequency of 10% or greater) were fatigue (19%), headache (15%), and nausea (11%). Most adverse events experienced were mild to moderate in severity. Five percent of subjects experienced a serious adverse event. Seventeen subjects discontinued for adverse events.

The frequencies of adverse reactions commonly associated with ribavirin therapy (rash, cough, anaemia, dyspnoea, insomnia, and anxiety) were higher for subjects who received ribavirin than for subjects who did not.

DAKLINZA in combination with SUNVEPRA: The safety of DAKLINZA 60 mg once daily in combination with SUNVEPRA was assessed in 918 subjects with chronic HCV infection in four open-label clinical trials [HALLMARK DUAL (AI447028), HALLMARK NIPPON (AI447026), AI447017, AI447011]. Median duration of study therapy was 24 weeks.

The most common adverse events (frequency of 10% or greater) were headache (23%), fatigue (17%), diarrhoea (15%), nasopharyngitis (14%), and nausea (10%). Most adverse events were mild to moderate in severity.

Six percent of subjects experienced a serious adverse event (SAE). Three percent of subjects discontinued for adverse events; the most common adverse events leading to discontinuation were increased ALT and increased AST.

In the HALLMARK DUAL study during the first 12 weeks of treatment, rates of adverse reactions were similar between subjects treated with placebo and subjects treated with DAKLINZA in combination with SUNVEPRA.

DAKLINZA in Combination with SUNVEPRA, Peginterferon Alfa, and Ribavirin

The safety of DAKLINZA 60 mg once daily in combination with SUNVEPRA, peginterferon alfa, and ribavirin was assessed in 398 subjects with chronic HCV genotype 1 or 4 infection in an open-label clinical trial [HALLMARK QUAD (AI447029)]. Median duration of study therapy was 24 weeks.

The most common adverse events (frequency of 15% or greater) were fatigue (42%), headache (31%), pruritus (26%), asthenia (24%), influenza-like illness and insomnia (each in 22%), rash (21%), anaemia (19%), cough (18%), dry skin (18%), diarrhoea (18%), nausea (17%), alopecia, irritability, and pyrexia (each in 16%), and myalgia (15%). Most adverse events experienced were mild to moderate in severity.

Six percent of subjects in HALLMARK QUAD experienced an SAE. Five percent of subjects discontinued for adverse events. The most common adverse events leading to discontinuation were rash, malaise, vertigo, and neutropenia.

Adverse events occurring at frequency of 5% or greater in integrated data from 4 studies of DAKLINZA in combination with SUNVEPRA, in Study AI444040 of DAKLINZA in combination with sofosbuvir, or in the HALLMARK QUAD study of DAKLINZA in combination with SUNVEPRA, peginterferon alfa, and ribavirin are presented in Table 12.

Table 12: Adverse Events Reported in ≥5% of Subjects in integrated data from 4 Clinical Trials of DAKLINZA in Combination with SUNVEPRA, from 4 Clinical Trials of DAKLINZA in Combination with Sofosbuvir, and in the HALLMARK QUAD study of DAKLINZA in Combination with SUNVEPRA, Peginterferon alfa and Ribavirin

Adverse Event	DAKLINZA in Combination with SUNVEPRA Percent with Adverse Event ^a n= 918	DAKLINZA and Sofosbuvir		DAKLINZA, SUNVEPRA, Peginterferon Alfa, and Ribavirin Percent with Adverse Event ^d n= 398
		With Ribavirin Percent with Adverse Event ^b n= 203	Without Ribavirin Percent with Adverse Event ^c n=476	
<i>General Disorders and Administration Site Conditions</i>				
Fatigue	16.9	29.1	22.7	41.5
Asthenia	4.9	0	0.4	24.1
Influenza-like Illness	2.9	1.0	1.5	22.4
Pyrexia	6.2	3.9	1.1	16.1
Pain	0.7	1.0	0.8	5.3

Adverse Event	DAKLINZA in Combination with SUNVEPRA Percent with Adverse Event ^a n= 918	DAKLINZA and Sofosbuvir		DAKLINZA, SUNVEPRA, Peginterferon Alfa, and Ribavirin Percent with Adverse Event ^d n= 398
		With Ribavirin Percent with Adverse Event ^b n= 203	Without Ribavirin Percent with Adverse Event ^c n=476	
<i>Gastrointestinal Disorders</i>				
Diarrhoea	14.5	12.8	8.0	17.6
Nausea	10.1	15.8	13.9	16.6
Constipation	6.8	6.4	2.5	3.5
Abdominal Pain Upper	5.6	3.9	1.5	5.3
Flatulence	2.7	2.0	3.2	0.8
Gastrooesophageal Reflux Disease	2.1	3.4	1.3	1.5
<i>Nervous System Disorders</i>				
Headache	23.2	27.1	18.1	31.2
Dizziness	5.9	6.9	3.8	8.0
<i>Psychiatric Disorders</i>				
Insomnia	6.5	8.9	5.3	22.4
Depression	2.3	3.9	1.7	8.5
Anxiety	2.0	4.9	1.9	3.3
Irritability	1.9	2.5	1.7	16.1
<i>Musculoskeletal and Connective Tissue Disorders</i>				
Arthralgia	6.3	7.4	6.1	10.1
Myalgia	5.1	2.0	2.9	15.3
Back Pain	4.7	5.4	4.2	7.3
<i>Skin and Subcutaneous Tissue Disorders</i>				
Pruritus	6.0	4.9	2.3	26.1
Rash	3.8	5.9	2.9	20.6
Dry Skin	2.6	3.4	0	17.8
Alopecia	3.8	2.0	1.5	16.1
<i>Respiratory, Thoracic and Mediastinal Disorders</i>				
Cough	6.3	9.4	2.9	18.3
Dyspnoea	2.1	5.9	1.3	12.3
Dyspnoea Exertional	0.5	2.5	0	5.3
<i>Infections and Infestations</i>				
Nasopharyngitis	13.7	3.4	4.0	1.5
Upper Respiratory Tract Infection	5.2	6.4	3.4	3.0
Urinary Tract Infection	2.1	1.0	2.3	2.0

Adverse Event	DAKLINZA in Combination with SUNVEPRA Percent with Adverse Event ^a n= 918	DAKLINZA and Sofosbuvir		DAKLINZA, SUNVEPRA, Peginterferon Alfa, and Ribavirin Percent with Adverse Event ^d n= 398
		With Ribavirin Percent with Adverse Event ^b n= 203	Without Ribavirin Percent with Adverse Event ^c n=476	
<i>Blood and Lymphatic System Disorders</i>				
Anaemia	1.1	17.2	0.2	19.3
Neutropenia	0.2	0	0.2	14.8
Thrombocytopenia	1.1	0.5	0	6.0
<i>Investigations</i>				
Increase in ALT	6.9	0	0	1.3
Weight Decreased	0.7	1.0	0.4	6.5
<i>Metabolic and Nutrition Disorders</i>				
Decreased Appetite	3.4	3.0	1.3	11.8
<i>Eye Disorders</i>				
Dry Eye	0.4	1.0	0.4	5.3

^a Integrated data from studies HALLMARK DUAL, HALLMARK NIPPON, AI447017, and AI447011.

^b Integrated data from Study AI444040, and ALLY-1.

^c Integrated data from Study AI444040, ALLY-3, and ALLY-2.

^dStudy HALLMARK QUAD.

Less Common Adverse Reactions: Additional adverse reactions observed in clinical trials of DAKLINZA combination therapy with SUNVEPRA or sofosbuvir occurring in less than 5% of subjects are eosinophilia and increased AST. These events have been included because of their seriousness or assessment of potential causal relationship to the regimen.

Postmarketing Experience

The following events have been identified during postapproval use of DAKLINZA:

Hepatobiliary disorders: hepatitis B reactivation (see PRECAUTIONS).

Daclatasvir and sofosbuvir regimen when administered with amiodarone

Cardiac arrhythmias

Cardiac arrhythmias including severe bradycardia and heart block have been observed in patients receiving amiodarone with DAKLINZA and sofosbuvir. (See PRECAUTIONS and INTERACTIONS WITH OTHER MEDICINES.)

Daclatasvir and asunaprevir regimen

Skin and subcutaneous tissue disorders: erythema multiforme.

Laboratory Findings

Selected treatment-emergent grade 3-4 laboratory abnormalities observed in HCV-infected subjects treated with DAKLINZA combination therapy are presented in Table 13.

Table 13: Selected Treatment-Emergent Grade 3-4 Laboratory Abnormalities in Clinical Trials of DAKLINZA in Combination with SUNVEPRA or with Sofosbuvir

Parameter ^a	Percent with Abnormality		
	DAKLINZA in Combination with SUNVEPRA ^b n= 918	DAKLINZA and Sofosbuvir (with or without Ribavirin) n= 679 ^c	DAKLINZA, SUNVEPRA, Peginterferon Alfa, and Ribavirin n=398
ALT, increased (>5× ULN)	4%	0.7%	3%
AST, increased (>5×ULN)	3%	0.7%	3%
Total bilirubin, increased (>2.5× ULN)	1%	4.6%	1%

^a Laboratory results were graded using the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 1.0.

^b Integrated data from studies HALLMARK DUAL, HALLMARK NIPPON, AI447017, and AI447011

^c Studies AI444040, ALLY-3, ALLY-2 and ALLY-1.

DOSAGE AND ADMINISTRATION

DAKLINZA is for oral administration and may be taken with or without food.

The recommended dose of DAKLINZA is 60 mg once daily. DAKLINZA must be administered in combination with other agents [see Table 14]. For specific dose recommendations for other agents in the regimen, refer to the respective prescribing information.

Dosing recommendations in Table 14 include patients co-infected with human immunodeficiency virus (HIV). For dosing recommendations with specific HIV antiviral agents, refer to INTERACTIONS WITH OTHER MEDICINES (see Table 11).

Table 14: Recommended Regimens with DAKLINZA 60 mg Once Daily Combination Therapy

HCV Genotype	Prior Treatment	Treatment	Duration
Genotype 1 or 3 ^a	None, or failed protease inhibitor and/or peginterferon alfa/ribavirin, or failed sofosbuvir/ribavirin	DAKLINZA and sofosbuvir ^b	12 weeks
Genotype 1b	None, or failed peginterferon alfa/ribavirin	DAKLINZA and SUNVEPRA	24 weeks
Genotype 1 or	None, or failed	DAKLINZA , SUNVEPRA,	24 weeks

HCV Genotype	Prior Treatment	Treatment	Duration
4	peginterferon alfa/ribavirin	peginterferon alfa, and ribavirin	

^a For genotype 3 patients with cirrhosis: consider prolonging treatment duration to 24 weeks.

^b For patients with Child-Pugh A cirrhosis: consider adding ribavirin to the DAKLINZA/sofosbuvir 12-week regimen.
 For patients with Child-Pugh B cirrhosis or patients with post-liver transplant recurrence of HCV infection: ribavirin should be added to the DAKLINZA/sofosbuvir 12-week regimen.
 For patients with Child-Pugh C cirrhosis: prolong treatment duration to 24 weeks and add ribavirin to the DAKLINZA/sofosbuvir regimen. For patients who cannot tolerate ribavirin, 24-week treatment without ribavirin may be considered.

Ribavirin Dosing Guidelines

The dose of ribavirin, when combined with DAKLINZA, is weight-based (1,000 or 1,200 mg in patients <75 kg or ≥75 kg, respectively). Refer to the prescribing information of ribavirin.

Dose Modification, Interruption, and Discontinuation

Once therapy is started, dose modification of DAKLINZA is not recommended. Treatment interruption should be avoided; however, if treatment interruption of any agent in the regimen is necessary because of adverse reactions, DAKLINZA should not be given as monotherapy.

Discontinuation of therapy is recommended for patients experiencing confirmed virologic breakthrough (greater than 1 log₁₀ IU/mL increase in HCV RNA from nadir).

Concomitant therapy

Strong inhibitors of cytochrome P450 enzyme 3A4 (CYP3A4): The dose of DAKLINZA should be reduced to 30 mg once daily when coadministered with strong inhibitors of CYP3A4 (using the 30 mg tablet; DAKLINZA tablets should not be broken). See INTERACTIONS WITH OTHER MEDICINES. Coadministration with strong or moderate CYP3A4 inhibitors is contraindicated with regimens that include SUNVEPRA.

Moderate inducers of CYP3A4: The dose of DAKLINZA should be increased to 90 mg once daily (using the 90 mg tablet or one 60 mg and one 30 mg tablet; DAKLINZA tablets should not be broken) when coadministered with moderate inducers of CYP3A4 [see INTERACTIONS WITH OTHER MEDICINES]. Coadministration with moderate CYP3A4 inducers is contraindicated with regimens that include SUNVEPRA.

OVERDOSAGE

There is limited clinical experience with overdose of DAKLINZA. In phase 1 clinical trials, healthy subjects who received up to 100 mg for up to 14 days or single doses up to 200 mg had no unexpected adverse events.

There is no known antidote for overdose of DAKLINZA. Treatment of overdose with DAKLINZA should consist of general supportive measures, including monitoring of vital signs and observation of the patient's clinical status. Because daclatasvir is highly protein bound (>99%) and has a molecular weight greater than 500, dialysis is unlikely to significantly reduce plasma concentrations of the drug.

For information on the management of overdose, contact the Poison Information Centre on 131126 (Australia).

PRESENTATION AND STORAGE CONDITIONS

DAKLINZA is supplied as tablets containing 60 mg daclatasvir (equivalent to 66 mg daclatasvir dihydrochloride), 30 mg daclatasvir (equivalent to 33 mg daclatasvir dihydrochloride) or 90 mg daclatasvir (equivalent to 99 mg daclatasvir dihydrochloride).

DAKLINZA tablets are supplied in PVC/PCTFE (Aclar)/Al blister packs and are available in three strengths:

- 60 mg daclatasvir tablets are light green biconvex pentagonal debossed with “BMS” on one side and “215” on the other side. Available in packs of 7 and 28 tablets.
- 30 mg daclatasvir tablets are green biconvex pentagonal debossed with "BMS" on one side and "213" on the other side. Available in packs of 7 and 28 tablets.
- 90 mg daclatasvir tablets are light green biconvex round embossed with “BMS” on one side and “011” on the other side. Available in packs of 7 and 28 tablets.

Store DAKLINZA tablets below 30° C.

NAME AND ADDRESS OF SPONSOR

Bristol-Myers Squibb Australia Pty Ltd
Level 2, 4 Nexus Court
MULGRAVE VIC 3170

POISON SCHEDULE OF THE MEDICINE

Schedule 4

DATE OF INCLUSION IN THE ARTG

25 June 2015

DATE OF MOST RECENT AMENDMENT

13 January 2017

DAKLINZA[®] and SUNVEPRA[®] are registered trademarks of Bristol-Myers Squibb